Publication Type : Review Article
Publisher : Innovare Academic Sciences Pvt Ltd
Source : International Journal of Current Pharmaceutical Research
Url : https://doi.org/10.22159/ijcpr.2021v13i6.1916
Keywords : Alzheimer's disease (AD), β-amyloid (Aβ), Tau proteins, Recent advance
Campus : Faridabad
School : School of Medicine
Department : Pharmacology
Year : 2021
Abstract :
The management of Alzheimer's disease (AD) has been a long-standing challenge and area of interest. Advances in knowledge of the pathogenesis of disease and an increase in disease burden have prompted investigation into innovative therapeutics over the last two decades. Current approved therapies are symptomatic treatments having some effect on cognitive function. Therapies that target β-amyloid (Aβ) have been the focus of efforts to develop a disease modification treatment for AD but these approaches have failed to show any clinical benefit so far. Beyond the 'Aβ hypothesis', there are a number of newer approaches to treat AD. This short review will summarize approved drug therapies, recent clinical trials and new approaches for the treatment of AD.
Cite this Research Publication : Arvind Narwat, Vivek Sharma, Suneel Kumar, Seema Rani, Recent Advances Inpharmacotherapy of Alzheimer’s Disease, International Journal of Current Pharmaceutical Research, Innovare Academic Sciences Pvt Ltd, 2021, Https://doi.org/10.22159/ijcpr.2021v13i6.1916